# Nutraceuticals for the management of weight and inflammation-related complications in obesity: a pediatric perspective. Systematic review and network meta-analysis

**Authors:** Gianvincenzo Zuccotti, Alessandro Gatti, Virginia Rossi, Erika Cordaro, Valeria Calcaterra

PMC · DOI: 10.3389/fnut.2026.1715574 · Frontiers in Nutrition · 2026-02-12

## TL;DR

This study reviews nutraceuticals for managing obesity and related inflammation, finding L-carnitine most effective in reducing weight and improving metabolic markers in children and adults.

## Contribution

The study provides a network meta-analysis of nutraceuticals for obesity management, focusing on pediatric populations and identifying L-carnitine as the most effective.

## Key findings

- L-carnitine significantly reduced body weight, BMI, and metabolic markers like HOMA-IR and LDL-C.
- Inulin and omega-3 fatty acids had modest effects, while butyrate improved BMI and waist circumference in children.
- Vitamin B showed limited impact, and higher dosages of supplements were often needed to achieve clinical targets.

## Abstract

Obesity, defined as excess body fat that impairs health, is a major public health challenge associated with metabolic and inflammation-related complications across the lifespan. Conventional treatments often show limited long-term efficacy, leading to growing interest in complementary strategies. Nutraceuticals have been studied for their potential in weight management and metabolic improvement. This systematic review and network meta-analysis evaluates the role of nutraceuticals in obesity management, with attention also given to pediatric populations.

We performed a systematic review and network meta-analysis (NMA) following Cochrane and PRISMA-NMA 2020 guidelines. Eligible randomized and non-randomized trials enrolled children or adults with overweight/obesity, testing nutraceuticals (inulin, butyrate, long-chain omega-3 fatty acids, vitamin B, carnitine) versus placebo or standard care. Primary outcomes included anthropometric, metabolic, and inflammatory markers. The protocol was registered in PROSPERO (ID: CRD420251151333).

L-carnitine emerged as the most effective and consistent intervention, producing significant reductions in body weight, body mass index (BMI), waist circumference, fasting blood glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and LDL-Cholesterol (LDL-C), along with a significant increase in HDL-Cholesterol (HDL-C). Inulin and long-chain omega-3 fatty acids (LC n3-PUFA) exhibited modest or non-significant effects on most outcomes, although LC n3-PUFA significantly reduced triglyceride levels. Butyrate demonstrated beneficial effects on BMI and waist circumference in children, whereas vitamin B showed limited impact. Dose–response analyses confirmed the efficacy of L-carnitine at relatively low dosages, while other supplements required higher intakes without achieving the predefined clinical targets.

This NMA shows heterogeneous effects of nutraceuticals on obesity-related outcomes. L-carnitine emerged as the most consistent intervention, while LC n3-PUFA, inulin, butyrate, and vitamin B provided more limited benefits. Preliminary evidence suggests potential age-related differences, highlighting the need for further studies to define age-specific and tailored strategies for obesity management.

## Linked entities

- **Chemicals:** butyrate (PubChem CID 104775), vitamin B (PubChem CID 936), carnitine (PubChem CID 288)
- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, LPL (lipoprotein lipase) [NCBI Gene 4023] {aka HDLCQ11, LIPD}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CXCR6 (C-X-C motif chemokine receptor 6) [NCBI Gene 10663] {aka BONZO, CD186, CDw186, STRL33, TYMSTR}, LIPE (lipase E, hormone sensitive type) [NCBI Gene 3991] {aka AOMS4, FPLD6, HSL, LHS, REH}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PYY (peptide YY) [NCBI Gene 5697] {aka PYY-I, PYY1}
- **Diseases:** hypoxia (MESH:D000860), metabolic (MESH:D008659), fatigue (MESH:D005221), overweight (MESH:D050177), excess weight gain (MESH:D015430), steatohepatitis (MESH:D005234), Obesity (MESH:D009765), NAFLD (MESH:D065626), endothelial dysfunction (MESH:D014652), dyslipidemia (MESH:D050171), inflammation (MESH:D007249), cardiometabolic complications (MESH:D024821), fibrosis (MESH:D005355), hypertriglyceridemia (MESH:D015228), chronic (MESH:D002908), T2DM (MESH:D003924), adipose tissue dysfunction (MESH:D018205), Excess weight (MESH:D015431), Insulin (MESH:D007333), hypertrophy (MESH:D006984), hyperinsulinemia (MESH:D006946), hypertension (MESH:D006973), endotoxemia (MESH:D019446)
- **Chemicals:** Inulin (MESH:D007444), acetyl-CoA (MESH:D000105), arachidonic acid (MESH:D016718), free fatty acids (MESH:D005230), EPA (MESH:D015118), aldosterone (MESH:D000450), triglyceride (MESH:D014280), Omega-3 fatty acids (MESH:D015525), glucose (MESH:D005947), SCFAs (MESH:D005232), acetate (MESH:D000085), lipid (MESH:D008055), DHA (MESH:D004281), LPS (MESH:D008070), propionate (MESH:D011422), carbohydrate (MESH:D002241), Butyrate (MESH:D002087), L-carnitine (MESH:D002331), eicosanoid (MESH:D015777), B1, B6, B9, and B12 (-)
- **Species:** Lactobacillus (genus) [taxon 1578], Homo sapiens (human, species) [taxon 9606], Enterovirus C (no rank) [taxon 138950]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937135/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937135/full.md

## References

71 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937135/full.md

---
Source: https://tomesphere.com/paper/PMC12937135